EP
CLDX icon

Eversept Partners’s Celldex Therapeutics CLDX Stock Holding History

Eversept Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.5M Sell
1,785,941
-2,075
-0.1% -$67K 3.45% 7
2026
Q1 		$56.7M Buy
1,788,016
+353,291
+25% +$9.63M 2.99% 9
2025
Q4 		$39M Buy
1,434,725
+280,805
+24% +$7.4M 1.96% 14
2025
Q3 		$29.9M Buy
1,153,920
+315,184
+38% +$7.3M 2.06% 17
2025
Q2 		$17.1M Buy
838,736
+142,237
+20% +$2.77M 1.57% 22
2025
Q1 		$12.6M Sell
696,499
-23,337
-3% -$521K 1.28% 27
2024
Q4 		$18.2M Buy
719,836
+154,934
+27% +$4.21M 1.61% 13
2024
Q3 		$19.2M Sell
564,902
-68,113
-11% -$2.6M 1.32% 20
2024
Q2 		$23.4M Sell
633,015
-78,100
-11% -$2.95M 1.6% 16
2024
Q1 		$29.8M Sell
711,115
-42,992
-6% -$1.77M 1.99% 14
2023
Q4 		$29.9M Buy
754,107
+165,964
+28% +$4.88M 2.63% 13
2023
Q3 		$16.2M Sell
588,143
-197,597
-25% -$6.19M 1.37% 19
2023
Q2 		$26.7M Buy
785,740
+96,064
+14% +$3.24M 2.23% 13
2023
Q1 		$24.8M Buy
689,676
+130,902
+23% +$5.65M 1.73% 15
2022
Q4 		$24.9M Sell
558,774
-67,598
-11% -$2.41M 2.18% 13
2022
Q3 		$17.6M Buy
626,372
+73,984
+13% +$2.27M 1.53% 15
2022
Q2 		$14.9M Sell
552,388
-84,065
-13% -$2.44M 1.06% 30
2022
Q1 		$21.7M Buy
636,453
+43,975
+7% +$1.41M 1.66% 21
2021
Q4 		$22.9M Buy
+592,478
New +$25.8M 1.46% 20
2020
Q4 		– Sell
-150,494
Closed -$2.23M – 63
2020
Q3 		$2.23M Sell
150,494
-562,204
-79% -$6.59M 0.5% 35
2020
Q2 		$9.27M Buy
+712,698
New +$3.16M 1.27% 21

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eversept Partners's CLDX Position: Q2 2026 in Review

Eversept Partners reduced its Celldex Therapeutics (CLDX) stake by 0.12% in Q2 2026, selling an estimated $67K and leaving 1,785,941 shares worth $66.5M. The position accounts for 3.45% of the portfolio, ranked #7.

Eversept Partners first reported a position in CLDX in Q2 2020 and has held it in 21 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Eversept Partners held 1,785,941 shares of Celldex Therapeutics worth $66.5M as of Q2 2026.
  • Eversept Partners sold 2,075 Celldex Therapeutics shares in Q2 2026, an estimated $67K.
  • Celldex Therapeutics made up 3.45% of Eversept Partners's portfolio in Q2 2026, its #7 holding.
  • Eversept Partners first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.